Identification of a Selective RORγ Ligand that Suppresses T$_H$17 cells and Stimulates T Regulatory Cells

Laura A. Solt, **Naresh Kumar**, **Yuanjun He**, **Theodore M. Kamenecka**, **Patrick R. Griffin**, and **Thomas P. Burris**
The Scripps Research Institute, Jupiter, FL 33458

Abstract

Nuclear Receptors (NRs) are ligand-regulated transcription factors, many of which are validated targets for clinical purposes. The retinoic acid receptor-related orphan nuclear receptors alpha and gamma t (RORα and RORγt) are considered the master regulators of development of T$_H$17 cells, a subset of T cells that have been implicated in the pathology of several autoimmune diseases, including multiple sclerosis (MS) and rheumatoid arthritis (RA). We report here the identification of a novel RORγ-specific synthetic ligand, SR1555, which not only inhibits T$_H$17 cell development and function, but also increases the frequency of T regulatory cells. Our data suggests synthetic RORγ ligands can be developed that target both suppression of T$_H$17 and stimulation of T regulatory cells offering key advantages in development of therapeutics targeting autoimmune diseases.

T$_H$17 cells are a subset of CD4$^+$ T cells that are critically dependent upon the nuclear receptors (NR) retinoic acid receptor-related orphan receptors alpha and gamma t (RORα and RORγt), and have been demonstrated to produce several proinflammatory cytokines, including IL-17A, IL-17F, IL-21, and IL-22(1–6). While their normal function is mediating immune defense against extracellular bacteria, aberrant T$_H$17 cell function has been implicated in a variety of autoimmune diseases, including multiple sclerosis (MS) and rheumatoid arthritis (RA). Autoimmune disease is thought to arise when the equilibrium between effector and regulatory T cells is disrupted.

T$_H$17 cells can be generated from naïve precursors in the presence of TGFβ and IL-6 or IL-21(7). However, since TGFβ is also the critical cytokine regulating the development of Foxp3$^+$ T regulatory cells, the development of one lineage over the other is dependent on the environmental milieu. Given this reciprocal relationship between T regulatory cells and T$_H$17 cells, it is still unclear of all of the factors that mediate the expansion of one population over the other. Since T$_H$17 cells play a central role in the development of several autoimmune diseases, identification of synthetic modulators that can inhibit T$_H$17 cell differentiation and function would have significant therapeutic value. We recently identified SR1001, a first-in-class, high affinity synthetic RORα/γ inverse agonist. SR1001 was effective at suppressing T$_H$17 cell differentiation and function *in vitro* and *in vivo* through direct inhibition of RORα and RORγ(8). Given the important role of RORα in the regulation of circadian rhythm and metabolism, there was some concern that a dual ROR-selective inverse agonist could cause undesirable side effects, suggesting that a RORγ-selective compound would be more appropriate (9).

SUPPORTING INFORMATION

Supporting Information is available is available free of charge *via* the Internet at http://pubs.acs.org.

Concurrent with our characterization of SR1001, several other groups identified RORγ-specific inverse agonists(10, 11). Similar to SR1001, these ligands inhibited T$_H$17 cell development and function. Therefore, in order to investigate the specific effects of RORα versus RORγ in T$_H$17 cell development, and alleviate activity at RORα, we performed further modifications to our initial lead compound, T0901317. Previously, we demonstrated that the benzenesulphonamide liver X receptor (LXR) agonist, T0901317, acted as an inverse agonist at RORα and RORγ(12). Due to its mixed pharmacology, it was unsuitable for specifically evaluating ROR effects. Compounds were identified using a screening approach similar to SR1001 and a RORγ-selective inverse agonist, SR1555, was identified (Fig. 1a). A screen of SR1555 in a GAL4-NR chimeric co-transfection assay demonstrated that SR1555 was devoid of LXR, FXR, and RORα activity, but it repressed the activity at RORγ in a dose dependent manner (IC$_{50}$ ~ 1.5 μM) (Fig. 1b). Next we examined the direct binding of SR1555 to RORα and RORγ in competitive radioligand binding assays. SR1555 was only able to displace [^{3}H]T0901317 from the ligand binding domain (LBD) of RORγ (IC$_{50}$ = 1μM; Fig. 1c) and not RORα (data not shown) confirming that SR1555 was indeed specific for RORγ.

Since RORα and RORγ are critical regulators of IL-17 gene expression, we examined whether SR1555 would affect RORα- and RORγ-dependent regulation of an IL-17 promoter driven luciferase reporter construct. HEK293 cells were transiently transfected with an IL-17 reporter, either full-length RORα or RORγ, and treated with an increasing concentration of SR1555(8). In a dose dependent manner, SR1555 suppressed IL-17 promoter driven activity by RORγ but not RORα, further confirming that SR1555 is indeed a RORγ-specific inverse agonist (Fig. 1d). Finally, using EL4 cells, a murine thymoma which endogenously express RORα, RORγt, and IL-17A, we examined whether SR1555 affected endogenous IL-17 gene expression(8). EL4 cells were treated with DMSO or SR1555 for 24 hours and analyzed for *Il17a* gene expression by quantitative real-time PCR. SR1555 inhibited *Il17a* gene expression by greater than 70%, demonstrating that SR1555 can inhibit the expression of this T$_H$17 mediated cytokine (Fig. 1e). Together, these data indicate that SR1555 specifically targets RORγ and inhibits its transcriptional activity leading to suppression of IL-17 gene expression.

Given that SR1555 was an effective inhibitor of endogenous IL-17 gene expression in EL4 cells, we next examined whether SR1555 would affect the differentiation of T$_H$17 cells *in vitro*. Murine splenocytes were cultured under T$_H$17 polarizing conditions (TGFβ and IL-6) for three days in the presence of SR1555 or vehicle control (DMSO). Real-time RTPCR analysis revealed that while SR1555 inhibited the mRNA expression of *Il17a*, it was less effective at inhibiting *Il17f*, *Il21*, and *Il22* (Fig 2a). While the effects of SR1555 are distinct from those observed with our dual RORα/γ inverse agonist, SR1001, or other previously published RORγ-ligands, our data suggests that ROR ligands with differing RORα/γ selectivity may display differential effects on T$_H$17 cytokine gene expression. It may also be the case that differential effects may be observed with different chemical classes of ROR ligands as has been observed with other nuclear receptor ligands.

Next, we examined the effects of SR1555 on IL-17 protein expression. Again, splenocytes were cultured under T$_H$17 polarizing conditions for four days in the presence of SR1555 or vehicle control for the full time course (Fig. 2b) or without ligand until 24 hours prior to completion of the experiment (compound added after day 3, Fig. 2c). Using intracellular cytokine FACS analysis, we determined that SR1555 was effective at inhibiting IL-17 protein expression when added at the initiation of T$_H$17 cell differentiation (Fig. 2b) and when SR1555 was added 24 hours prior to the completion of the experiment (Fig. 2c). In order to clarify that the effects observed in the cultures was not due to toxicity of the compounds, we analyzed the cultures for the expression of Annexin V and propidium

iodide, markers of cell death, using flow cytometry. SR1555 did not induce cell death during T_H17 cell differentiation relative to the DMSO control (Fig. 2d). To date, most RORγ-specific compounds have been evaluated as "preventative" measures. Currently, there is little data evaluating the efficacy of ROR-selective drugs once the initiation of T_H17 development has begun. Our data suggests that RORγ-specific inverse agonists will be effective at inhibiting T_H17 cell-mediated cytokine responses once the differentiation process has commenced (Fig. 2c).

Upon antigen exposure and in the presence of TGFβ, both *Foxp3* and *Rora/γt* are upregulated. Therefore, the environmental cues associated with the concentration of TGFβ dictates the balance between T_H17 and T regulatory cell differentiation. In light of the reciprocal relationship between these two cell types, we assessed whether SR1555 affected the development of T regulatory cells *in vitro*. Splenocytes were cultured under T regulatory cell polarizing conditions (TGFβ and IL-2) for 3 days. Quantitative RTPCR analysis revealed that SR1555 effectively increased the gene expression of *Foxp3* while simultaneously suppressing the gene expression of *Rorγt* (Fig. 3a). To determine whether the gene expression data would correlate with protein expression, we again cultured splenoyctes for 5 days under T regulatory cell polarizing conditions in the presence of DMSO or SR1555 and examined the expression of Foxp3 by intracellular cytokine FACS analysis. Similar to the gene expression data, SR1555 treatment increased the frequency of T regulatory cells as evidenced by the almost two-fold increase in the expression of Foxp3$^+$ T cells in the splenocyte culture (Fig. 3b). This result was surprising given that all previously described RORγ ligands have no effect on T regulatory cell populations *in vitro* (8). Furthermore, these effects were not mediated through RARα or RXRα, given that activation of RAR has been demonstrated to be a mediator of inducible T regulatory cells (Supplementary Figure 1)(13). Therefore, our data suggests that all RORγ-selective ligands are not created equally. While ligands like digoxin and ursolic acid may be touted as RORγ-selective and look similar in reporter gene assays, compounds of different chemical classes may have differential effects(10, 11). Thus, while inhibition of RORγ alone may be sufficient to inhibit T_H17 responses, unique RORγ-specific ligands, like SR1555 may hold utility in the generation of T regulatory cells.

Since the nuclear receptors RORα and RORγt are considered the master regulators of T_H17 cell development, generation of synthetic ligands designed to modulate the activity of the RORs is a promising strategy for therapeutics aimed at T_H17-mediated diseases. Although several NRs, including RARα (retinoic acid receptor alpha), VDR (vitamin D receptor), and GR (glucocorticoid receptor), have been demonstrated to regulate the effector functions of fully differentiated T cells, these NRs are not required for T cell development as RORα and RORγt are for T_H17 cells(14). In fact, in the absence of RARα and VDR, T cells develop normally(15, 16). Furthermore, direct targeting of these NRs can lead to a global inhibition of T cell function as GR and VDR are present in all T cell types, not just T_H17 cells(14, 16). Therefore, the ultimate goal for the treatment of autoimmune diseases is to not only inhibit the cell type(s) responsible for the disease state, but to help the body regain its immune homeostasis, which may involve increasing the T regulatory cell population. Recently, we and others have reported the identification and characterization of ligands specific to RORα and/or RORγt that inhibit T_H17 cell differentiation and function(8, 10, 11, 17). None of these compounds altered T regulatory cell function. In this report, we identified a RORγ-specific inverse agonist, SR1555, with unique features. Similar to the other ROR-ligands published, SR1555 inhibits T_H17 cell differentiation and function. However, SR1555 treatment also enhances the induction of inducible T regulatory cells *in vitro*. Interestingly, SR1555 is structurally similar to the most recent RORγ selective ligand we recently reported, SR2211, but this compound does not alter T regulatory cell proliferation (Supplementary Figure 2). These data suggests that the T_H17 vs. T regulatory effects of

RORγ ligands are separable and can likely be optimized individually. Of course, a ROR ligand that affects the T_H17/Treg cell ratio by directly targeting both cell types could be of particular benefit in treatment of autoimmunity. Our data suggests that each ROR ligand is unique and may have differential effects at RORα and/or RORγ, that could result in some ligands being considered more attractive candidates for therapeutics aimed at treating T_H17-mediated diseases.

METHODS

Synthesis of SR1555

Step 1: 1,1,1,3,3,3-Hexafluoro-2-(4-iodophenyl)propan-2-ol—

To 2-(4-Amino-phenyl)-1,1,3,3,3-hexafluoropropan-2-ol (commercially available) in DMF was added a solution of sodium nitrite (1.2 eq) in water and 6M hydrochloric acid (3 eq), while maintaining the temperature between 0~5 °C in an ice bath. The reaction mixture was stirred for 30 min, and then potassium iodide (1.5 eq) was added in portions. The resulting reaction mixture was stirred overnight at rt. The reaction mixture was diluted with Et_2O, washed several times with a solution of saturated sodium thiosulphate and treated with Na_2SO_4. The solvent was evaporated in vacuo leaving a crude oil and the product, 1,1,1,3,3,3-Hexafluoro-2-(4-iodophenyl)propan-2-ol, was isolated by flash chromatography on silica gel (~5%EtOAc/Hex) to obtain the title compound.

Step 2: 1,1,1,3,3,3-hexafluoro-2-(4′-((1-(acetyl) piperazine) methyl)-[1,1′-biphenyl]-4-yl)propan-2-ol—

To 4-bromomethylphenylboronic acid was added 1,4-dioxane, followed by addition of K_2CO_3 (4.0 eq), of 1-acetyl-piperazine (1.1 eq) and potassium iodide (2 % weight). The mixture was allowed to stir overnight at rt (~23° C) under argon balloon. To the mixture was then added water (1 : 4, water/dioxane) and $Pd(PPh_3)_4$ (5 mol%). The mixture was then purged of air via vacuum line and argon balloon, fitted with air cooled condenser, and heated at reflux under argon balloon for 1.5 h. The reaction mixture was allowed to cool and was then subsequently extracted with excess EtOAc, keeping the organic phase, which was washed with brine and dried over Na_2SO_4, and concentrated in vacuo. The crude residue was purified by reverse-phase preparative HPLC to provide the TFA salt of the title compound as a colorless solid. ^{1}H NMR (400MHz, DMSO-d_6) δ 7.92-7.65 (m, 7 H), 7.66 (d, J=8.0 Hz, 2 H), 4.61-4.49 (m, 3 H), 4.11-4.09 (m, 1 H), 3.50-2.91 (m, 6 H), 2.08 (s,

3H); ^{13}C NMR (100MHz, DMSO-d$_6$) δ 168.53. 158.49 (q, J=33.7 Hz, CF$_3$COOH), 140.86, 140.08, 131.96, 130.23, 129.12, 127.43, 127.25, 126.96, 122.91, 117.97 (CF$_3$COOH), 76.78 (q, J=30 Hz, CF$_3$), 58.43, 50.71, 50.33, 42.49, 37.71, 20.85; ESI-MS (m/z): 460.94 [M+1]$^+$.

Mice

Male C57BL/6 mice (8 weeks old) were purchased from Jackson Laboratory (Bar Harbor, ME). All mice were maintained and experiments were performed in specific pathogen free environments in accordance with protocols approved by the Institutional Animal Care and Use Committee.

Cell Culture and Cotransfections

Cotransfection assays were performed as previously described in HEK293 cells (Gal4 cotransfection assay or IL-17 luciferase reporter)(8). HEK293 and the mouse lymphoma EL4 (ATCC) cells were maintained in DMEM supplemented with 10% FBS plus antibiotics (penicillin and streptomycin; Invitrogen)..

Splenocyte Differentiation

Splenocytes were differentiated under the following conditions: iTreg - 10μg mL^{-1} anti-IFNγ, 10μg mL^{-1} anti-IL-4, and 2ng mL^{-1} TGFβ (R&D Systems); 20ug mL^{-1} anti-IFNγ, 20ug mL^{-1} anti-IL-4, 1ng mL^{-1} TGFβ, and 10ng mL^{-1} IL-6 (R&D Systems) for T$_H$17 conditions. All cultures were stimulated with 1μg mL^{-1} anti-CD3 (eBiosciences) and 1μg mL^{-1} anti-CD28 (eBiosciences). Four to five days after activation, all cells were restimulated with 5ng mL^{-1} phorbol-12-myristate-13-acetate (PMA) (Sigma) and 500ng mL^{-1} ionomycin (Sigma) for 2 hours with the addition of GolgiStop (BD Bioscience) for an additional 2 hours before intracellular staining. Cells were cultured in RPMI 1640 medium (Invitrogen) with 10% FBS and antibiotics.

Flow cytometry and antibodies

Single cell suspensions prepared from spleen were stained with fluorophore-conjugated monoclonal antibodies: FITC anti-CD4 (GK1.5, eBioscience), phycoerythrin-conjugated anti-mouse IL-17A (eBio17B7, eBioscience), and Alexafluor 647 anti-Foxp3 (FJK-16s, eBioscience) along with the Foxp3 staining buffer set (eBioscience). Annexin V and propidium iodide staining was performed using the FITC AnnexinV Apoptosis Detection Kit II (BD Pharmingen). Flow cytometric analysis was performed on a BD LSRII (BD Biosciences) instrument and analyzed using FlowJo software (TreeStar).

Quantitative RT-PCR

RNA extraction and QRT-PCR analysis was performed as previously described(8).

Statistical analysis

All data are expressed as the mean ± s.e.m. (*n=3* or more). Statistical analysis was performed using an unpaired Student's *t*-test.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003; 421:744–748. [PubMed: 12610626]

2. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005; 201:233–240. [PubMed: 15657292]

3. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008; 453:106–109. [PubMed: 18362914]

4. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006; 126:1121–1133. [PubMed: 16990136]

5. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006; 24:677–688. [PubMed: 16782025]

6. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol. 2007; 19:652–657. [PubMed: 17766098]

7. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441:235–238. [PubMed: 16648838]

8. Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidovic D, Schurer SC, Xu J, Wagoner G, Drew PD, Griffin PR, Burris TP. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011; 472:491–494. [PubMed: 21499262]

9. Jetten AM, Kurebayashi S, Ueda E. The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol. 2001; 69:205–247. [PubMed: 11550795]

10. Xu T, Wang X, Zhong B, Nurieva RI, Ding S, Dong C. Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein. J Biol Chem. 2011; 286:22707–22710. [PubMed: 21566134]

11. Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, Chow J, Manel N, Ciofani M, Kim SV, Cuesta A, Santori FR, Lafaille JJ, Xu HE, Gin DY, Rastinejad F, Littman DR. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature. 2011; 472:486–490. [PubMed: 21441909]

12. Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez RD, Burris TP, Griffin PR. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-(alpha)/(gamma) inverse agonist. Mol Pharmacol. 2010; 77:228–236. [PubMed: 19887649]

13. Hall JA, Grainger JR, Spencer SP, Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunity. 2011; 35:13–22. [PubMed: 21777796]

14. Winoto A, Littman DR. Nuclear hormone receptors in T lymphocytes. Cell. 2002; 109(Suppl):S57–66. [PubMed: 11983153]

15. Hall JA, Cannons JL, Grainger JR, Dos Santos LM, Hand TW, Naik S, Wohlfert EA, Chou DB, Oldenhove G, Robinson M, Grigg ME, Kastenmayer R, Schwartzberg PL, Belkaid Y. Essential role for retinoic acid in the promotion of CD4(+) T cell effector responses via retinoic acid receptor alpha. Immunity. 2011; 34:435–447. [PubMed: 21419664]

16. Ooi JH, Chen J, Cantorna MT. Vitamin D regulation of immune function in the gut: why do T cells have vitamin D receptors? Mol Aspects Med. 2012; 33:77–82. [PubMed: 22079836]

17. Kumar N, Lyda B, Chang MR, Lauer JL, Solt LA, Burris TP, Kamenecka TM, Griffin PR. Identification of SR2211: A Potent Synthetic RORgamma-Selective Modulator. ACS Chem Biol. 2012; 7:672–677. [PubMed: 22292739]

Figure 1.
Characterization of SR1555. a) Structure of SR1555. b) Full length G6Pase and GAL4-
LXRα, RORα, RORγ, and FXR co-transfection assays in HEK293 cells illustrating the
specificity SR1555. (*n=8*). c) Competition radio-labeled binding assays illustrating the direct
binding of SR1555 to the LBD of RORγ only. C.P.M., counts per minute. (*n=4*). d) SR1555
dose-dependently inhibits an IL-17 promoter driven luciferase construct only in the presence
of RORγ. (*n=4*). e) EL4 cells were treated with DMSO or SR1555 (10μM) for 24 hours
followed by mRNA analysis of IL-17A by RTPCR (*n=4*). (**p<0.05*).

Figure 2.
Effects of SR1555 during T_H17 cell differentiation. a) Real time – RTPCR analysis of splenocytes cultured under T_H17 polarizing conditions in the presence of DMSO or SR1555 (10μM) for the duration of the time course. Data are normalized to GAPDH. ($n=3$). b) The effect of SR1555 (10μM) on IL-17A cytokine expression during murine T_H17 cell differentiation. Intracellular cytokine staining on splenocytes treated with DMSO or SR1555 for the duration of the experiment. Cells were grated on CD4$^+$ T cells. Graph on the right summarizes IL-17 expression normalized to DMSO. ($n=3$, $*p<0.05$). c) Intracellular cytokine staining on splenocytes treated with DMSO or SR1555 (10μM) for 24 hours prior to FACS analysis. Cells were grated on CD4$^+$ T cells. Graph on the right summarizes IL-17 expression normalized to DMSO. ($n=3$, $*p<0.05$). d) The effect of SR1555 (10μM) on the viability of T_H17 cells. Cells were gated on AnnexinV and propidium iodide positive cells. Graph depicts percent of positive cells normalized to DMSO. ($n=3$).

Figure 3.
SR1555 increases the frequency of iTregs. a) RTPCR analysis of splenocytes cultured under T regulatory cell polarizing conditions in the presence of DMSO or SR1555 (10μM) for the duration of the time course. Data are normalized to GAPDH. (*n=3*). b) The effect SR1555 (10μM) on the expression of Foxp3$^+$ cells during the differentiation of iTregulatory cells. Intracellular cytokines staining on splenocytes differentiated under iTreg conditions for 5 days treated with vehicle control (DMSO) or SR1555 for the duration of the experiment. Cells were gated on CD4$^+$ T cells. Graphs to the right of the FACS plots summarize the Foxp3$^+$ expression normalized to DMSO. (*n=3*, *p<0.05*).